Ace Therapeutics, a provider of preclinical stroke research services, has announced an expanded portfolio of hemorrhagic stroke models designed to help researchers investigate intracerebral hemorrhage (ICH) and develop new treatments. The company's offerings include both in vitro and in vivo models that replicate key aspects of ICH pathophysiology, such as hematoma expansion, neuronal cell death, oxidative stress, blood-brain barrier disruption, and neuroinflammation.
The in vitro models include hemoglobin, hemin, and autologous blood models, each tailored for high-throughput screening and mechanistic studies. These models simplify complex biological systems while retaining disease-relevant features, making them suitable for targeted pathway research. For in vivo studies, Ace Therapeutics provides animal models across multiple species, including rodents and large animals. Core models include whole blood injection, collagenase-induced hemorrhage, and microballoon insertion, which mimic acute hematoma accumulation, localized microvascular rupture, and space-occupying effects, respectively. These models replicate increased intracranial pressure and reduced cerebral blood flow, critical factors in acute brain injury.
The company emphasizes collaboration with researchers to select the optimal model based on study goals, whether focusing on acute versus chronic phases, molecular versus hemodynamic analysis, or efficacy testing. This tailored approach aims to maximize translational value, bridging preclinical research and clinical application. By leveraging these custom models and specialized CRO services, available through their website at https://www.acetherapeutics.com, the research community can overcome preclinical barriers and accelerate progress toward treatments for hemorrhagic stroke.
The implications of this announcement are significant for the field of stroke research. Hemorrhagic stroke, particularly intracerebral hemorrhage, has limited treatment options and high mortality rates. The availability of validated preclinical models that closely mimic human pathophysiology can enhance the predictive power of efficacy studies, potentially reducing the failure rate of candidate therapies in clinical trials. By providing a comprehensive suite of models and customization flexibility, Ace Therapeutics positions itself as a key partner for biotech companies, pharmaceutical firms, and academic researchers dedicated to advancing ICH therapeutics. The ability to precisely control hematoma volume and evaluate interventions for swelling and hemodynamic changes in both small and large animals allows for more rigorous testing of novel drugs and devices. This could lead to breakthroughs in managing acute brain injury and improving patient outcomes. Ultimately, these services may help close the gap between laboratory discoveries and clinical applications, addressing a critical need in stroke medicine.
